Comparative Pharmacology
Head-to-head clinical analysis: BRINZOLAMIDE versus KEVEYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINZOLAMIDE versus KEVEYIS.
BRINZOLAMIDE vs KEVEYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
1 drop of 1% solution in the affected eye(s) twice daily.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Clinical Note
moderateBrinzolamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Fluconazole
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Category A/B
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
"The metabolism of Fluconazole can be decreased when combined with Brinzolamide."